FDA approves Actavis ADHD drug
MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic version of a drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Wednesday.
Actavis announced the FDA approval of methylphenidate hydrochloride extended-release capsules in the 20-mg, 30-mg and 40-mg strengths, a generic version of Novartis’s Ritalin LA. Actavis said it was the first to file for regulatory approval of the drug in those three strengths, thus entitling it to 180 days of market exclusivity in which it will directly compete with the branded version.
The drug had sales of $80.7 million during the 12-month period ended in September, according to IMS Health.
Study analyzes potential benefits of MTM integration
The role of the pharmacist has evolved considerably over the past decade, and few things exemplify that evolution more than pharmacists taking an active role in patients’ medication therapies and consulting with them one-on-one.
Researchers from pharmacy schools at the University of Minnesota, the University of Iowa, the University of Southern California and the University of Oklahoma collected data for “environmental scans” from U.S. MTM providers and payers using self-administered online surveys conducted between 2007 and 2010, according to a white paper published in the Journal of the American Pharmacists Association.
The study found a need to integrate MTM between organizations and patients serviced, partnering organizations and collaborating healthcare providers, as well as that “a ‘channel of distribution’ is emerging in which organizational relationships and cost efficiencies will be important considerations in the near term.” The researchers suggested that customer portfolio management and transaction cost economics would help to integrate MTM into the U.S. healthcare system.
Still, retailers across the country have embraced MTM as a way to improve medication adherence. Under a collaboration that began last year, Walgreens and Decatur, Ga.-based DeKalb Medical have the retailer’s pharmacists helping patients understand and comply with their therapies following treatment at the hospital. In November 2011, just three months after the collaboration started, the two reported that it had led to improved patient care and satisfaction.
In September 2011, Rite Aid announced that it had joined the Diabetes Prevention and Control Alliance, an initiative created by UnitedHealth Group, to have pharmacists offer diabetes consultations and MTM services to patients at several of its stores in New York and Washington.
ReportersNotebook — Chain Pharmacy, 1/9/12
SUPPLIER NEWS — Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said. The features will give pharmacies an outreach channel to improve their bin management and will-call services, as well as allow them to easily identify aging prescriptions and use the Mscripts mobile application to remind customers to pick up their prescriptions.
Ranbaxy Labs got the green light from the Food and Drug Administration to launch its generic version of Pfizer’s cholesterol-lowering drug Lipitor on Nov. 30, the day Pfizer’s patent on the drug expired. The FDA approved Ranbaxy’s atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths. New Brunswick, N.J.-based Ohm Labs manufactures the drug. Ranbaxy said that through an agreement with Teva Pharmaceuticals USA, a portion of the profits from sales of the drug during the exclusivity period will go to Teva, though terms of the agreement were not disclosed. Lipitor had sales of $7.8 billion during the 12-month period ended in September, according to IMS Health.
Mylan said its subsidiary has launched a generic version of a hypertension treatment. Mylan Pharmaceuticals launched and began shipping amlodipine besylate and atorvastatin calcium tablets in various strengths. The drug is a generic version of Pfizer’s Caduet, which had U.S. sales of approximately $339 million for the 12 months ended Sept. 30, according to IMS Health.